(Q39770190)

14 September 2017

title

Comparison of Costs and Benefits of Breast Cancer Screening with Mammography, Ultrasonography, and MRI (English)

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

27 November 2024

1 reference

Stephen Feig

1 reference

14 September 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21419333

27 November 2024

publication date

1 March 2011

1 reference

14 September 2017

March 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21419333

full work available at URL

27 November 2024

https://api.elsevier.com/content/article/PII:S0889854511000106?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

https://api.elsevier.com/content/article/PII:S0889854511000106?httpAccept=text/plain

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Obstetrics and Gynecology Clinics of North America

27 November 2024

published in

1 reference

14 September 2017

1 reference

14 September 2017

1 reference

14 September 2017

page(s)

179-96, ix

1 reference

The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cost analysis of the National Breast and Cervical Cancer Early Detection Program: selected states, 2003 to 2004

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Increased benefit from shorter screening mammography intervals for women ages 40-49 years

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Estimation of currently attainable benefit from mammographic screening of women aged 40-49 years

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Diagnostic performance of digital versus film mammography for breast-cancer screening

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cost-effectiveness of digital mammography breast cancer screening

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Screening mammography in women aged 40-49 years: analysis of cost-effectiveness

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cost Analysis of Aggressive Breast Cancer Screening

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Screening for breast cancer

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Mammographic screening of women aged 40-49 years. Benefit, risk, and cost considerations

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cost-Effectiveness of Extending Screening Mammography Guidelines To Include Women 40 to 49 Years of Age

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Breast cancer mortality after screening mammography in British Columbia women

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Screening mammography beginning at age 40 years: a reappraisal of cost-effectiveness

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Sensitivity analysis in the cost-effectiveness of breast cancer screening

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

The cost-effectiveness of breast cancer screening

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Computer-aided detection of breast cancer: a cost-effectiveness study

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Induced costs of low-cost screening mammography

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Performance benchmarks for screening mammography

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Identifying minimally acceptable interpretive performance criteria for screening mammography

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

The probably benign assessment

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Use of breast core biopsy in the United States: results of a national survey

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

The evolving practice pattern of the breast surgeon with disappearance of open biopsy for nonpalpable lesions.

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

A prospective review of the decline of excisional breast biopsy

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Mammographically detected breast cancer. Benefits of stereotactic core versus wire localization biopsy

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Stereotactic breast biopsy

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

A comparison of Medicare reimbursement and results for various imaging-guided breast biopsy techniques

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Stereotactic core biopsy reduces the reexcision rate and the cost of mammographically detected cancer

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Reducing the cost of diagnosis of breast carcinoma: impact of ultrasound and imaging-guided biopsies on a clinical breast practice

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Stereotactic breast biopsy as an alternative to open excisional biopsy

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Estimating the cost-effectiveness of stereotaxic biopsy for nonpalpable breast abnormalities: a decision analysis model

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Needle core biopsy guided with mammography: a study of cost-effectiveness

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Screening mammography: costs and use of screening-related services

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Ten-year risk of false positive screening mammograms and clinical breast examinations.

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cost-effectiveness of image-guided core needle biopsy versus surgery in diagnosing breast cancer

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

American Cancer Society guidelines for breast cancer screening: update 2003.

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

American College of Radiology guidelines for breast cancer screening

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Screening for breast cancer: an update for the U.S. Preventive Services Task Force

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Service screening with mammography in Northern Sweden: effects on breast cancer mortality - an update

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

The Canadian National Breast Screening Study: a critical review

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Breast cancer: computer simulation method for estimating optimal intervals for screening

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Breast cancer screening by mammography in Norway. Is it cost-effective?

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Breast cancer screening and cost-effectiveness; policy alternatives, quality of life considerations and the possible impact of uncertain factors

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Advanced breast cancer and its prevention by screening

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Is mass screening for breast cancer cost-effective?

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cost-effective management of breast cancer

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cost-benefit determinations in screening mammography

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Breast Cancer Screening With Imaging: Recommendations From the Society of Breast Imaging and the ACR on the Use of Mammography, Breast MRI, Breast Ultrasound, and Other Technologies for the Detection of Clinically Occult Breast Cancer

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Familial risks of breast cancer

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Lobular Carcinoma In Situ of the Breast

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Breast cancer risk associated with proliferative breast disease and atypical hyperplasia

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Mammographic Density and the Risk and Detection of Breast Cancer

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Tailored supplemental screening for breast cancer: what now and what next?

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Breast lesions detected with MR imaging: utility and histopathologic importance of identification with US.

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Analysis of clinically occult and mammographically occult breast tumors

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Effect of mammographic breast density on breast cancer screening performance: a study in Nijmegen, The Netherlands

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers

27 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Imaging of the radiographically dense breast

27 November 2024

101

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Analysis of parenchymal density on mammograms in 1353 women 25-79 years old.

27 November 2024

102

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Malignant breast masses detected only by ultrasound. A retrospective review

27 November 2024

103

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Occult cancer in women with dense breasts: detection with screening US--diagnostic yield and tumor characteristics.

27 November 2024

104

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Incidental findings on sonography of the breast: clinical significance and diagnostic workup

27 November 2024

105

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Clinically and mammographically occult breast lesions: detection and classification with high-resolution sonography

27 November 2024

106

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Clinical utility of bilateral whole-breast US in the evaluation of women with dense breast tissue

27 November 2024

107

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations

27 November 2024

108

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Mammography and subsequent whole-breast sonography of nonpalpable breast cancers: the importance of radiologic breast density

27 November 2024

109

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Using sonography to screen women with mammographically dense breasts

27 November 2024

110

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Auditing and benchmarks in screening and diagnostic mammography

27 November 2024

113

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer

27 November 2024

114

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Breast screening with ultrasound in women with mammography-negative dense breasts: evidence on incremental cancer detection and false positives, and associated cost

27 November 2024

115

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Providing professional mammography services: financial analysis

27 November 2024

116

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts

27 November 2024

118

1 reference

https://api.crossref.org/works/10.1016/J.OGC.2011.02.009

27 November 2024

Identifiers

1 reference

14 September 2017

1 reference